Founded in 1985, amfAR is dedicated to ending the global AIDS epidemic through innovative research. With the freedom and flexibility to respond quickly to emerging areas of scientific promise, amfAR plays a catalytic role in accelerating the pace of HIV/AIDS research and achieving real breakthroughs. amfAR-funded research has increased our understanding of HIV and has helped lay the groundwork for major advances in the study and treatment of HIV/AIDS. Since 1985, amfAR has invested $275 million in its mission and has awarded grants to more than 2,000 research teams worldwide. For more information visit www.amfar.org.
amfAR supports innovative research into the improvement of HIV/AIDS prevention and treatment strategies -- strategies that might ultimately result in viral eradication. The Foundation plays a vital role in advancing emerging ideas by providing seed money to researchers for early-stage projects, and enables young researchers to establish their careers in HIV/AIDS. With amfAR's support, researchers can gather the preliminary data required by other funders of AIDS research, thus allowing a relatively small amfAR investment to be leveraged into large-scale studies of lifesaving interventions.
Since its early days, amfAR has helped healthcare workers and AIDS organizations in developing countries maximize local resources and implement effective research, treatment, prevention, and education strategies. An amfAR initiative called TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) is a network of clinics, hospitals, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments throughout Asia and the Pacific. The MSM Initiative, established in 2007, strives to reduce worldwide rates of HIV infection among men who have sex with men (MSM) in developing countries through small grants to grassroots groups that help expand HIV education and prevention.
Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation's public policy program is currently engaged in efforts to secure necessary increases in funding for HIV/AIDS research, including vaccine and microbicide research; implement a comprehensive national prevention strategy, including repeal of the current ban on federal funding for syringe exchange programs; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS.
Through its education and information program, amfAR distributes information on important AIDS-related research, treatment, prevention, and policy issues to a range of audiences and generates awareness of the need for better treatment and prevention methods. The Foundation also helps raise standards of HIV/AIDS care by providing medical education to doctors and healthcare workers in the U.S. and abroad.
In the Spotlight
amfAR funds cutting-edge research projects through generous contributions raised during special events and black-tie galas such as the amfAR New York Gala, Cinema Against AIDS, and Trek amfAR. amfAR's 15th annual Cinema Against AIDS gala, held May 22, 2008, at the Cannes Film Festival, raised more than $10 million for amfAR's life-saving AIDS research programs. Events such as these help bring the community together and honor those who have contributed to the fight against HIV/AIDS.
120 Wall Street, 13th Floor
New York, NY 10005-3908
(212) 806-1600 (phone)
(212) 806-1601 (fax)
1150 17th St. NW, Ste. 406
Washington, DC 20036-4622
(202) 331-8600 (phone)
(202) 331-8606 (fax)
21st. Fl., Ste. 2104
388 Sukhimvit Road
+66 2663 7561 (phone)
+66 2663 7562 (fax)
USA Toll-Free Number: 1-800-39-amfAR
In the course of its 23-year history, amfAR has contributed to numerous significant advances in HIV prevention, treatment and care. These accomplishments have helped extend, improve, and save the lives of countless people around the world living with HIV/AIDS or vulnerable to HIV infection. Major achievements include:
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.